Latest news with #CSPCPharmaceuticalGroup
Reuters
30-07-2025
- Business
- Reuters
Madrigal signs potential $2 billion-plus deal with China's CSPC to develop liver drug
July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group ( opens new tab that could be worth more than $2 billion for the Chinese company if it results in a new drug for a serious form of liver disease. The agreement gives Madrigal exclusive global rights to SYH2086, an oral GLP-1 receptor agonist designed to mimic the effects of popular weight-loss medications such as Ozempic and Wegovy. The drug is currently being tested in lab studies. Madrigal plans to combine SYH2086 with its flagship therapy Rezdiffra, the only U.S. Food and Drug Administration-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver scarring. MASH, formerly known as nonalcoholic steatohepatitis (NASH), is a progressive liver disease linked to obesity, diabetes and high cholesterol. It can lead to liver failure and is a growing cause of the organ's transplants globally. "We believe a combination of Rezdiffra and SYH2086 has the potential to deliver a best-in-class oral treatment for patients with MASH," Madrigal CEO Bill Sibold said on Wednesday. Under the deal, Madrigal will pay CSPC $120 million upfront and potentially another $2 billion if certain development and commercial milestones are met. GLP-1 drugs, originally developed for diabetes and obesity, are being tested for MASH due to their weight-loss and metabolic benefits. Novo Nordisk's ( opens new tab semaglutide and Eli Lilly's (LLY.N), opens new tab tirzepatide are among the most advanced GLP-1 candidates in late-stage trials for MASH. The deal between Madrigal and CSPC is part of a broader trend of Western drugmakers tapping Chinese biotech firms for innovative therapies, particularly in fast-growing areas such as GLP-1 drugs. CSPC, which recently signed a separate multibillion-dollar AI-driven drug discovery pact with AstraZeneca (AZN.L), opens new tab, is among several Chinese companies developing next-generation GLP-1 drugs.
Economic Times
13-06-2025
- Business
- Economic Times
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally," AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
Business Recorder
13-06-2025
- Business
- Business Recorder
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally,' AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
Business Insider
02-06-2025
- Business
- Business Insider
Analysts Conflicted on These Healthcare Names: CSPC Pharmaceutical Group (OtherCHJTF) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSPC Pharmaceutical Group (CHJTF – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: CSPC Pharmaceutical Group (CHJTF) Jefferies analyst Chu Wang downgraded CSPC Pharmaceutical Group to Sell yesterday and set a price target of HK$5.00. The company's shares closed last Tuesday at $0.81. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSPC Pharmaceutical Group with a $0.84 average price target. Moderna (MRNA) In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on Moderna. The company's shares closed last Friday at $26.56. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. Moderna has an analyst consensus of Hold, with a price target consensus of $49.36, implying an 87.4% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Business Insider
01-06-2025
- Business
- Business Insider
Citi Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
In a report released yesterday, from Citi maintained a Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report), with a price target of HK$9.20. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Citi, CSPC Pharmaceutical Group also received a Buy from Morgan Stanley's Yolanda Hu in a report issued yesterday. However, on the same day, Macquarie maintained a Hold rating on CSPC Pharmaceutical Group (Other OTC: CHJTF). The company has a one-year high of $0.96 and a one-year low of $0.44. Currently, CSPC Pharmaceutical Group has an average volume of 35.52K.
